Tuesday, February 9, 2010, 11:06pm EST - Canadian Markets are closed.
To create a watchlist or portfolio of shares, Sign-in or Register

Incyte Corporation (INCY)

 At 16:00 EST: 10.28 USD  Up 0.32 (3.21%)  
MORE ON INCY
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Incyte Corporation (NGM:INCY) Delayed quote dataEdit
After Hours: 9.96 Down 0.32 (3.11%) as of 5:00pm EST on 02/09/10
Last Trade: 10.28 USD
Trade Time: 4:00PM EST
Change: Up 0.32 (3.21%)
Prev Close: 9.96
Open: 10.23
Bid: 9.98 x 500
Ask: N/A
1y Target Est: 12.64
Day's Range: 10.07 - 10.45
52wk Range: 1.96 - 11.24
Volume: 2,102,388
Avg Vol (3m): 3,302,710
Market Cap: 1.22B
P/E (ttm): N/A
EPS (ttm): -1.76
Div & Yield: N/A (N/A%)
Incyte Corporation (INCY)
1d  5d  3m  6m  1y  2y  5y  max 
 Add INCY to Portfolio   Download Data

HEADLINES
• Incyte to Report 2009 Financial Results and 2010 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18
Business Wire (Tue 4:16pm)
• Nektar adds to board of directors
at bizjournals.com (Tue, Feb 2)
• Incyte Announces Redemption of Its 3½% Convertible Senior Notes Due 2011 and Its 3½% Convertible Subordinated Notes Due 2011
Business Wire (Thu, Jan 28)
• Eli Lilly Misses by a Penny
Zacks.com (Thu, Jan 28)
• Another Deal for Novartis
Zacks.com (Wed, Jan 20)
• Incyte to Present at the 28th Annual JPMorgan Healthcare Conference
Business Wire (Tue, Jan 5)
• Analysts Name Top Biotech Stocks for 2010: BioBuzz
at TheStreet.com (Tue, Jan 5)
• Lilly Prepares for Patent Loss in Psychosis Drug, Moves into Arthritis Market
at Seeking Alpha (Thu, Dec 24)
• Pharma Spreads Holiday Cheer in Bevy of Biotech Deals
at Seeking Alpha (Thu, Dec 24)
• Lightning Round OT: Kinder Morgan Energy, Incyte and More
at CNBC (Wed, Dec 23)
• Another Deal for Incyte
Zacks.com (Tue, Dec 22)
• Some Incyte Into Why These Drugs Rock
at Motley Fool (Tue, Dec 22)
• Deal activity lifts US stocks
at FT.com (Mon, Dec 21)
• INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
EDGAR Online (Mon, Dec 21)
• Pharma's Holiday Shopping Spree
at CNBC (Mon, Dec 21)
• Incyte shares rise on Eli Lilly deal
AP (Mon, Dec 21)
• A Slew of New Deals Move Pharma Stocks
Indie Research (Mon, Dec 21)
More Headlines for INCY...
ANALYST
EPS Est (next year) (Dec-09) : -1.61
EPS Est (in 2 years) (Dec-10) : -1.26
Avg Rec (current)*: 1.4
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Incyte Corporation, a drug discovery and development company, focuses on developing proprietary small molecule drugs to treat oncology, inflammation, and diabetes.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices